Genomictree Inc.
228760.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$249.88B
Close$
$-1440.93
113.9% downside
Current Fair Value
113.9% downsideOvervalued by 113.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $249.88 Billion |
|---|---|
| Enterprise Value | $232.45 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-374.27 |
| Beta | 2.25 |
| Outstanding Shares | 24,026,655 |
Return
| Return on Equity | -7.42% |
|---|---|
| Return on Assets | -7.26% |
| Return on Invested Capital | -11.61% |
Valuation & Multiples
| P/E Ratio | -30.22 |
|---|---|
| PEG | -42.63 |
| Price to Sales | 85.25 |
| Price to Book Ratio | 2.05 |
| Enterprise Value to Revenue | 78.89 |
| Enterprise Value to EBIT | -16.27 |
| Enterprise Value to Net Income | -26 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 6, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Genomictree Inc.
76 employees
CEO: Sung-Whan An Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to develop and market advanced detection tools for both oncological conditions and various infectious diseases. Its product line includes EarlyTect C, a screening...